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Stem cells are unspecialized cells that have been a major focus of the field of regenerative medicine, opening new
frontiers and regarded as the future of medicine. The ophthalmology branch of the medical sciences was the first
to directly benefit from stem cells for regenerative treatment. The success stories of regenerative medicine in
ophthalmology can be attributed to its accessibility, ease of follow-up and the eye being an immune-privileged
organ. Cell-based therapies using stem cells from the ciliary body, iris and sclera are still in animal experimental
stages but show potential for replacing degenerated photoreceptors. Limbal, corneal and conjunctival stem cells
are still limited for use only for surface reconstruction, although they might have potential beyond this. Iris pigment
epithelial, ciliary body epithelial and choroidal epithelial stem cells in laboratory studies have shown some promise
for retinal or neural tissue replacement. Trabecular meshwork, orbital and sclera stem cells have properties identical
to cells of mesenchymal origin but their potential has yet to be experimentally determined and validated. Retinal
and retinal pigment epithelium stem cells remain the most sought out stem cells for curing retinal degenerative
disorders, although treatments using them have resulted in variable outcomes. The functional aspects of the
therapeutic application of lenticular stem cells are not known and need further attention. Recently, embryonic stem
cell-derived retinal pigment epithelium has been used for treating patients with Stargardts disease and age-related
macular degeneration. Overall, the different stem cells residing in different components of the eye have shown
some success in clinical and animal studies in the field of regenerative medicine.Introduction
Pluripotency, the capacity to differentiate into multiple
lineages, and proliferation are two characteristic attri-
butes of stem cells. These cells are capable of replacing
damaged or diseased cells under certain circumstances.
Regenerative medicine or stem cell-based therapy has
now reached a state where ocular tissues damaged by
disease or injury can be repaired and/or regenerated.
The ease of access for the therapeutic procedure as well
as follow-up together with its immune-privileged status
makes the eye an ideal organ for studying regenerative
medicine. Such therapy involves various procedures
where stem cells are injected into both the cellular and
extracellular matrix microenvironments [1]. Corneal epi-
thelial cell transplantation has been the most widely
used stem cell-based therapy following bone marrow
transplantation.* Correspondence: drdebashish@narayananethralaya.com
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reproduction in any medium, provided the orStem cell-based treatment in ophthalmology follows
either a cell replacement therapy strategy or a strategy
involving trophic factor-based guidance cues. Through-
out treatment, outcomes depend on our in-depth know-
ledge of the disease, the source of stem cells, the mode
of treatment and the plausible mechanism driving the
therapeutic outcome [2].
In this review we discuss region-specific stem cell popu-
lations and their respective functions in cell-based therapy.
We also address possible hurdles to therapy and means to
overcome these in our pursuit of regenerative medicine
applications in the field of ophthalmology.Cornea (limbus and stroma)
The cornea is at the outermost surface of the eye and
safeguards transparency, which is crucial for vision. The
corneal stem cell population is located in the periphery
of the cornea, in the limbus; these cells are termed lim-
bal epithelial stem cells (LESCs) [3-6]. Stroma comprises
90% of the volume of the cornea and, unlike the self-
renewal of epithelia, the homeostasis of stroma is not
based on a cycle of cell death and mitotic renewal.entral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Stem cells in the corneal epithelium are located in the
basal layer of the limbal region at the corneal periphery,
called the palisades of Vogt [3]. These are visualized in
small clusters and are closely associated with the stromal
matrix and the basement membrane, thereby assisting in
cell-cell, cell-extracellular matrix and paracrine signaling
communication. The corneal epithelial basal layer is
composed mostly of transient amplifying cells at various
stages of maturity.
LESCs are identified by their elevated expression of an
isoform of the transcription factor p63 along with a high
nuclear to cytoplasmic ratio [7,8]. ABCG2 (ATP binding
cassette sub family G member 2) positivity has been de-
tected in LESCs as well as several other cells residing in
the suprabasal limbus and these markers have the poten-
tial to identify the LESC population based on their stain-
ing ability in clusters of progenitor-like cells in the
limbus [9,10]. Reports also indicate that Musashi-1, an
RNA binding protein, can be used to specifically stain
LESCs [11,12]. Corneal stem cells also express enolase,
cytokeratin (CK)19, and vimentin but do not express
CK3, CK12, or Connexin 43, which are present in cor-
neal epithelial cells [11,12].
Stromal multipotent clonal cells have been identified
and expanded to neurospheres in cultures [13,14]. Cor-
neal stromal stem cells are located in the anterior stroma
sub-adjacent to the basal side of the palisades of Vogt
[15]. Stem cells in the stroma were identified as a side
population using the DNA-binding dye Hoechst 33342.
These cells expressed genes encoding ABCG2, Bmi1,
CD166, c-kit, Pax6, Six2 and Notch1 as well as mesen-
chymal stem cell and early corneal developmental
markers. When differentiated, corneal stromal stem cells
expressed keratocyte markers such as keratocan,
ALDH3A1, CXADR, PTDGS and PDK4 [16].
Therapeutic implications
LESC deficiency is pathological, either partially or com-
pletely, and is caused by either mechanical injury or
chemical and thermal burns or acquired by diseases such
as aniridia and Stevens Johnson syndrome. Treatment of
such conditions involves LESC transplantation therapy.
LESCs from the healthy eye in unilateral cases of ocular
disease are expanded ex vivo for therapeutic purposes
using protocols involving amniotic membrane or fibrin in
the presence or absence of growth-arrested 3 T3 fibroblast
feeder layers. Alternative, experimental sources for LESCs
for cell-based therapy include buccal mucosal epithelial
cells, hair follicle stem cells, and human embryonic stem
cells (ESCs) [17,18]. Among non-limbal cell types, cul-
tured oral mucosal cells and conjunctival epithelial cells
have been transplanted to treat limbal stem cell deficiency
in humans [19,20].Recent research shows that the peripheral cornea con-
tains a higher density of keratocyte precursors with high
proliferative capacity. A three-dimensional construction
using corneal keratocyte precursors and gelatin hydro-
gels provided cues for attracting keratocytes and extra-
cellular matrix in scarred stroma [21]. Du and colleagues
[22] demonstrated restoration of corneal transparency,
stromal thickness and collagen fibril defects after inject-
ing corneal stromal stem cells in mice. If successful, such
therapy would eliminate the shortage of donor corneas
needed for transplantations. Although stem cell trans-
plantation is performed worldwide, variability in clinical
outcomes implies that standardized protocols need to be
established. Further validation and quality assessment
studies on these cell types could provide therapeutic so-
lutions for ocular surface reconstruction, and may also
provide insights into the feasibility of their use for re-
construction of tissues beyond the ocular surface.
Conjunctiva
The conjunctiva, apart from being a barrier to patho-
genic entry, is a highly vascularized connective tissue
that provides channels for proper flow of nutrients and
fluids. Conjunctival cells undergo renewal similar to the
corneal epithelium, but the source of the stem cells for
this remains elusive [23].
Identification and isolation
Conjunctival stem cells can differentiate into either
mucin-producing goblet cells or an epithelial cell. The
dividing basal cells migrate from the bulbar conjunctiva
to the corneal surface and differentiate. Conjunctival
epithelial cells are negative for CK3 and CK12 but posi-
tive for CK19. The stem cells residing in the fornical
niche can differentiate into epithelial cells as well as gob-
let cells, as shown in clonal culture assays. This provides
strong evidence that the stem cell population for con-
junctiva renewal is in the fornix region [24,25].
Therapeutic implications
Ocular processes that affect the cornea also affect the
conjunctiva. Conjunctival scarring, cicatricial pemphig-
oid, thickening, dry eye or mucin deficiency are some of
the conditions affecting the conjunctiva. Conjunctival
autografts, oral mucous membrane grafts, nasal turbin-
ate mucosa grafts and amniotic membrane are often
used to treat conjunctival stem cell deficiency and scar-
ring [18]. Conjunctival cells cultured on amniotic mem-
brane have been used for cell transplantation in patients
with limbal stem cell deficiency. Recent patient follow-
up reports have shown that transplantation of autolo-
gous conjunctival epithelial cells improved the clinical
parameters of total limbal stem cell deficiency with re-
spect to vision acuity, impression cytology and in vivo
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ex vivo (on amniotic membrane) in Dulbecco's modified
Eagle's medium with Ham’s 12 in the presence of epider-
mal growth factor, insulin, cholera toxin and hydrocorti-
sone to derive the corneal lineage; the cells were
transplanted after 2 weeks of culture. Ultrathin poly-
membrane (epsilon-caprolactone) substrate has also
been shown to support conjunctival epithelial cell prolif-
eration [27].
Iris
The iris divides the space between the cornea and lens
into anterior and posterior halves. The stroma and the
vasculature of the iris are developed from the anterior
region of the optic cup [28].
Identification and isolation
Iris pigment epithelial cells have the ability to grow in
spheres and express markers of neural stem/progenitor
cells such as Nestin, Msi and Pax6. Studies from mouse
iris have revealed that these cells can also be differenti-
ated to neuronal as well as glial lineages and express
markers such as Chx10, Rho, Otx2 and Olig2 [29].
Therapeutic implications
Though the iris pigment epithelial cells have potential to
be used in cell-based therapy, not much work on valid-
ation and quality assessment has been done. These cells
can be transdifferentiated into retinal neuronal cells ex-
pressing retinal-specific markers [30]. Further studies
are needed before iris pigment epithelial cells can be
used clinically.
Ciliary body
The ciliary body produces the aqueous humor and is in-
volved in regulating the aqueous flow, blood flow, intra-
ocular pressure and maintenance of the immune-
privileged status of the anterior chamber [31].
Identification and isolation
Ciliary body stem cells are derived from ciliary epithelium
and undergo lineage-specific differentiation to retinal
tissues. The ciliary-derived progenitor cell population
expresses neuronal/retinal markers such as Nestin,
Chx10 and Pax6. Ciliary epithelial cells can be cultured
in vitro, forming neurospheres expressing transcription
factors (Sox 2 and Pax 6) and retinal markers (Lhx2,
Dach1, Six 3) [32].
Therapeutic implications
During homeostasis ciliary epithelium maintains a bal-
ance between epithelial and neuronal cell types, whereas
during disease ciliary epithelium cells can act as donor
cells for retinal repair. Studies so far have revealed thatciliary epithelium cells differentiate well into the retinal
lineage cells that express retinal markers but do not in-
tegrate with existing retinal architecture. Recently, Gual-
doni and colleagues [33] and Yanagi and colleagues [34]
reported that ciliary epithelium cells lack the potential to
differentiate into photoreceptors, suggesting that the
cells need to be reprogrammed to be useful as a source
of new photoreceptors. Further studies are warranted so
we might realize the potential of these cells in clinics.
Cicero and colleagues [35] reported that, although ciliary
epithelium stem cells expressed retinal markers, each
cell contained pigments and had membrane interdigita-
tions and epithelial junctions. Ballios and colleagues [36]
showed that clonally derived retinal stem cell progeny
from ciliary epithelium can differentiate into mature
rhodopsin-positive cells using a combination of exogen-
ous culture additives (fibroblast growth factor, heparin,
retionic acid, taurine). Inoue and colleagues [37] demon-
strated that modulation of the retinal transcriptional fac-
tors OTX2, CRX and CHX10 increases the potential of
retinal stem cell progeny derived from the cilliary mar-
gin of adult human eye.
Trabecular meshwork
The trabecular meshwork (TM) is a tissue between the
cornea and iris in the anterior region that is responsible
for drainage of aqueous fluid. The balance between
aqueous secretion and outflow determines intraocular
pressure, which is a risk factor for the development of
glaucoma. TM cells help to remove debris in the circu-
lating aqueous humor [38].
Identification and isolation
TM cells express vimentin, non-muscle actin, aquaporin-
1, acetylated and acetoacetylated alpha-2 adrenergic re-
ceptor, matrix GLA protein and chitinase-3-like-1 [39-41].
Recently, the isolation and characterization of TM cells
have been widely studied. These studies suggest that TM
cells have stem cell-like properties, expressing mesenchy-
mal cell-associated markers such as CD73, CD90, and
CD105, and the ability to differentiate into adipocytes, os-
teocytes, and chondrocytes [38,42]. Further, studies
showed that TM stem cells isolated as a side population
or as clones expressed specific stem cell markers such as
ABCG2, Notch1, OCT-3/4, AnkG, and MUC1 [38]. These
stem cells could differentiate into the TM lineage and
expressed AQP1, CHI3L1, and TIMP3 markers and had a
phagocytic function [38,42].
Therapeutic implications
Lowering the intra-ocular pressure is an aim of treat-
ments for glaucoma. The idea for this came primarily
from the observation that TM cell division increased
after argon laser trabeculoplasty [43]. Topical and oral
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cal approaches (for example, implant blebs) are current
first-line treatments. A very recent study reported that
stem cells isolated from human TM and expanded
in vitro showed evidence of the ability to home to mouse
TM and differentiate into TM cells in vivo [44]. The ex-
panded TM stem cells expressed the stem cell markers
ABCG2, Notch1, and MUC1 and were positive for ex-
pression of the TM marker protein CHI3L1. These TM
cells were multipotent and had phagocytic properties
[38,45]. Some groups are working on transplanting TM
cells or TM progenitor cells combined with argon laser
trabeculoplasty as a novel cell-based therapy for glau-
coma [38,43-45].
Lens
The lens is composed of the lens capsule, epithelium
and fibers and, like the cornea, is transparent. Lens stem
cells are hypothesized to reside in the lens capsule, al-
though they have not yet been identified. It is plausible
that they come from the ciliary body, which is anatomic-
ally close to the lens [46].
Identification and isolation
Lens capsule regeneration has been shown to occur in
lower vertebrates from cells residing in the ciliary body.
The lens stem cells might thus reside in the lens capsule
[47,48]. Lens stem cells have not yet been identified.
Therapeutic implications
Lens progenitor cells have been derived from human
ESCs as well as induced pluripotent stem cells (iPSCs)
[48]. Lens stem cells are presumed to have a role in
maintaining the lens transparency and might be import-
ant in cataractogenesis or other lens abnormalities
Retina
The retina represents the connecting link between visual
input and image processing in the brain. Retinal diseases
mostly result in irreversible damage to the visual path-
way. Several studies in animal models have achieved
some amount of success using transplantation of photo-
receptors, endothelial cells and retinal pigment epithe-
lium (RPE) [17,48].
Therapeutic implications
Most therapeutic application studies have been conducted
on murine retinal disease models. Diseases in the inner
retina include retinopathy (ischemic conditions) and optic
neuropathy, which cause damage in the retinal ganglion
cells and amacrine cells [49]. Transplantation of bone
marrow-derived mesenchymal stem cells into the vitreous
of a retinal ischemia mouse model demonstrated ganglion
cell neuroprotection [50]. Cell transplantation in a retinaldegeneration model has shown promising visual outcomes
but the extent of the curative effect remained unclear
[51-55]. The injected stem cells integrated into the retinal
and subretinal microenvironment modulated differenti-
ation of different cell types [51,52]. These transplanted
cells integrate in a temporal-dependent manner that oc-
curs only during rod genesis.
Clinical trials using fetal retinal cells have been con-
ducted in patients with retinitis pigmentosa and age-
related macular degeneration. In recent work, the entire
retina has been replaced with differentiated stem cells
rather than just single cells [53]. The three-dimensional
neural retina was grown in culture from mouse ESCs
[54]. Bilayer cups developed through morphogenesis of
ESCs cultured with extracellular matrix. Most of the ef-
fects of transplantation seem to be based on the trophic
factors used rather than a cell integration effect. Further
studies and better sources of stem cells need to be inves-
tigated [55].Photoreceptors and retinal-pigmented epithelium
The current stem cell-based therapies for retinal diseases
focus on supplementing or replacing photoreceptors and
RPE in the affected retina.Therapeutic implications
Recently, safety and efficacy results were obtained from
a clinical trial of subretinal transplantation of RPE cells
derived from human ESCs. Several groups have shown
the capacity of human ESCs to differentiate into RPE
with variable success rates [56]. Recently, the differenti-
ation efficacy was increased 30-fold by adding vitamin
B3 and activin A protein [51]. Murine disease models
such as Leber's congenital amaurosis rat have been used
to study transplantation with differentiated retinal pre-
cursors; no teratoma formation was observed but the
curative outcome needs to be followed up [57].
Transplantation of stem cell-, stem cell precursor- and
iPSC-derived photoreceptors has resulted in functional
recovery in animal models of retinal degeneration. Stud-
ies by several groups have demonstrated integration of
photoreceptor precursors derived from postnatal retinas
into degenerated mouse retina [52,53,58,59]. Tucker and
colleagues [60] demonstrated that adult fibroblast-
derived iPSCs differentiated into retinal precursor cells
expressing retinal as well as photoreceptor markers
(Pax6, CRX, recoverin and rhodopsin). Moreover, re-
search has progressed from differentiating ESCs into
photoreceptor lineages to determining the type of cell
and day of culture required for successful transplantation
[61-63]. Investigating methods to improve and support
transplantation, Tucker and colleagues [64] demonstrated
that a xeno-free substrate and extracellular matrix-coated
Table 1 Ocular stem cells: locations, functions, markers and therapeutic development stage
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cells.
Cultured RPE cells were transplanted into a rat model
of age-related macular degeneration generated by defect-
ive photoreceptor phagocytosis [65]. The results revealed
clearing of photoreceptor debris and regaining of visual
function. Clinical trials on replacement of RPE in age-
related macular degeneration resulted in transient vision
recovery, with an autologous source providing better re-
sults [66].
Advanced Cell Technology Inc. (Marlborough, MA,
USA) is currently conducting a phase I/II clinical trial
on treating macular dystrophy using human ESC-
derived RPE cells [67,68]. Before RPE transplantation
can be used in humans, further studies are necessary to
determine how these cells can be integrated effectivelyTable 2 Future prospects for stem cell use for ocular cell ther
Cell source Diseases Site of
RPE cells Wet AMD Scaffol
Human embryonic-stem-cell-derived retinal epi-


























AMD, age-related macular degeneration; iPSC, induced pluripotent stem cell; RPE, reinto the retina without resulting in malignancy and im-
munogenicity [69].
Choroid
The choroid is derived from mesoderm and neuroecto-
derm. Choroidal stem cells obtained from murine stud-
ies reveal mesenchymal stem cell properties, expressing
markers such as Sca-1, CD90.2, CD44, CD105, CD73,
ABCG2, Six2, Notch1 and Pax6. We are still far from
understanding their proliferative and differentiation po-
tential [70].
Therapeutic implications
Choroidal and scleral cells have been differentiated into
retinal lineage cells under laboratory conditions [71].














brication processes, a novel biodegradable


















Figure 1 Schematic representation of sources and applications of ocular stem cells.
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liferative aspects, of these cells before they can be used
clinically.
Sclera
The sclera is continuous with the cornea and is com-
posed of fibrous material with viscoelastic properties. It
is responsible for maintaining ocular pressure. Scleral
stem cells have a mesenchymal origin and express
ABCG2, Six2, Pax6 and Notch1 [70].
Therapeutic implications
Diseases that cause distension of the sclera, such as my-
opia, might be repaired using scleral stem cells. These
might provide a source for bioengineering sclera for cell-
based therapy [70], but more studies are needed to de-
termine the role of scleral stem cells and treatment
implications.
Orbit
The orbit provides a scaffold for the eye. It is a bony
cavity that contains the eye, optic nerve, extra-ocularmuscles, nerves, fat and lacrimal gland. In recent years,
adipose tissue stem cells have been studied extensively,
and some research has been done on orbital adipose
stem cells. Diseases such as thyroid eye disease and ag-
gressive malignant tumors lead to neurological conse-
quences and blindness.Identification and isolation
It has recently been observed that orbital fat cells con-
tain stem cells. These are derived from neural crest cells,
which are mesodermal in origin [72]. Interestingly, re-
cent studies have isolated and characterized the orbital
fat-derived stem cells. They have demonstrated that or-
bital adipocytes are similar to bone marrow-derived
mesenchymal stem cells, sharing nearly 260 surface
markers with them [73,74]. Orbit fat-derived stem cells
have the potential to differentiate into osteoblasts, chon-
drocytes and adipocytes, and further culturing with cor-
neal epithelial cells changed their morphology to
polygonal epithelial-like cells. This was confirmed by
these cells expressing the epithelial cell marker zonal-
Figure 2 Status of ocular and non-ocular stem cell transplantation for anterior surface disorders of the eye. MSC, mesenchymal
stem cell.
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CK19 [74].
Therapeutic implications
Destruction of corneal epithelial cells results in loss of
vision. Stem cells isolated and expanded from the limbal
area of the ocular surface are able to repair the corneal
epithelium. However, obtaining healthy limbal stem cells
and immune tolerance are still issues. Recently, Lin and
colleagues [75] used orbital fat-derived stem cells to pro-
mote corneal tissue regeneration through a non-surgical
route. Topical administration of fat-derived stem cells
(mouse model) resulted in inhibition of inflammation
and corneal re-epithelization. Therefore, orbit adipocytes
are also potential candidates for cell therapy and tissue
engineering of corneal epithelium. Further research into
these progenitor cells may provide insight into patho-
logical processes in orbit and other ocular damage.
Conclusion
We provide comprehensive detail on the localization of
ocular stem cells and explain the therapeutic potential ofeach. Ocular diseases can be classified into vascular de-
fects, anatomical defects and neurodegenerative defects.
In order to address these defects, regenerative medicine
using cell replacement strategies could be highly benefi-
cial and effective. Identification of the proper sources of
stem cells is the first step towards this, followed by their
isolation and characterization. Ophthalmology is the
only branch of medical science that has so far gained
from the field of regenerative medicine. Limbal stem cell
transplantation is the only other cell-based transplantation
procedure, other than bone marrow transfusion, that has
been approved for patient care.
Tables 1 and 2 provide summaries of the present and
future prospects of stem cells for ocular therapy. Figure 1
depicts the locations of stem cells and their clinical ap-
plication status. Figures 2 and 3 highlight stem cell
sources used in ocular cell therapies for specific diseases.
In order to harness the potential of stem cell-based ther-
apy to provide and restore sight in blind patients, the
safety of the cells needs to be studied in detail. For the
successful utilization of stem cells for therapeutic pur-
poses, small molecules can be incorporated with or
Figure 3 Status of ocular and non-ocular stem cell transplantation for posterior chamber disorders of the eye. MSC, mesenchymal
stem cell.
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specific differentiation pathways [76]. These cells serve
to replace damaged cells and produce cytokines, growth
factors, and other trophic molecules [77]. Fundamental
studies are needed to unravel the roles of the Ivy league
signaling pathways such as the Notch, WNT, Jak-Stat,
tyrosine kinase, and Sonic hedgehog pathways. Also, al-
ternative sources of stem cells need to be explored for
their ability to integrate into the visual network. Basic
researchers and ophthalmologists worldwide share opti-
mism that stem cell therapy will in the future provide a
means to restore vision.
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